Why this East Bay drug maker's stock price nearly doubled last year
January 19, 2018 at 10:23 AM EST
The aesthetics market dominated by Botox is the billion-dollar target of Revance Therapeutics. But the Newark company's head-to-toe strategy includes therapeutic uses.